Pyxis Oncology
PYXS
88 hedge funds and large institutions have $29.6M invested in Pyxis Oncology in 2025 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 26 reducing their positions, and 22 closing their positions.
14% more call options, than puts
Call options by funds: $41K | Put options by funds: $36K
3.95% less ownership
Funds ownership: 53.06% → 49.11% (-3.9%)
11% less funds holding
Funds holding: 99 → 88 (-11)
19% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 26
40% less capital invested
Capital invested by funds: $49.2M → $29.6M (-$19.6M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
50% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.47M |
| 2 |
P8IP
Pier 88 Investment Partners
San Francisco,
California
|
+$390K |
| 3 |
Renaissance Technologies
New York
|
+$385K |
| 4 |
Morgan Stanley
New York
|
+$272K |
| 5 |
6CM
683 Capital Management
New York
|
+$180K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$939K |
| 2 |
Millennium Management
New York
|
-$661K |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$597K |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$365K |
| 5 |
PA
Perceptive Advisors
New York
|
-$294K |
PYXS Hedge Fund Activity: Q1 2025 in Review
88 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q1 2025, worth a combined $29.6M — down 40% from $49.2M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of PYXS and 11 opened new positions — a net loss of 11 holders — while 26 trimmed existing stakes and 21 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $1.47M. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $939K sold.
- 88 institutional investors held Pyxis Oncology (PYXS) as of Q1 2025, down from 99 in Q4 2024.
- Funds reported $29.6M of Pyxis Oncology stock for Q1 2025, down 40% quarter-over-quarter.
- 11 funds opened new Pyxis Oncology positions in Q1 2025 and 22 closed out, a net change of -11 holders.
- The largest Pyxis Oncology buyer in Q1 2025 was Tang Capital Management, an estimated $1.47M added.
- The largest Pyxis Oncology seller in Q1 2025 was Jacobs Levy Equity Management, an estimated $939K sold.
Based on aggregated 13F filings for Q1 2025.